All articles by Phillip Broadwith – Page 19
-
Business
Merck & Co doubles up on Ablynx research deal
Cancer nanobody R&D partnership could be worth €1.7 billion
-
Business
Stolen silicone secrets land worker in jail
Former Wacker employee sold formulae to South Korean firm KCC Silicones
-
Business
AstraZeneca ends R&D in India
Bangalore site will close with loss of 168 jobs. Some projects will transfer to UK
-
Business
Ashland cuts jobs in global reshuffle
Speciality chemicals maker will axe 800-1000 positions and relocate 800-1000 more during 2014
-
Business
US blocks imports from fourth Ranbaxy plant
FDA bans import of active ingredients from factory in Toansa, India
-
Business
Novartis and DSM trim jobs
Novartis to close US manufacturing site, both companies restructuring Swiss operations
-
Business
Plug and play redox enzymes
Technology profile: HydRegen is making cofactor-dependent catalysis cleaner
-
Business
US chemical spill contaminates water supplies
Life beginning to return to normal for locals after being without potable water for several days
-
Business
Novartis in the spotlight in mis-selling investigations
Crackdown on pharma marketing continues with US and Japanese cases
-
Business
Deadly explosion at Japanese silicon plant
Five killed and several more injured at Mitsubishi Materials site
-
Business
Thermo Fisher to sell three analytical divisions to GE Healthcare
Deal will help the firm complete its ongoing takeover of Life Technologies
-
Review
What a wonderful world: one man’s attempt to explain the big stuff
Don’t know much about a science book
-
Business
Lanzatech expands waste-to-chemicals range
Partnership with Evonik will see gas-guzzling microbes make polymer precursors
-
Business
Merck KGaA snaps up electronic materials specialist
Firm looks to bolster R&D by acquiring AZ Electronic Materials
-
Business
Nike eliminates water at new Taiwanese dyeing plant
ColorDry process uses supercritical CO2 to reduce waste and cut costs
-
Business
New wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels